Inflection Biosciences Limited
Inflection Biosciences is an early stage, drug development company which won Start-Up of the Year at the Pharma Industry Awards 2014. Due to the successful pre-clinical testing of treatments that it has licensed and hopes to bring to the market, the company has received upwards of €2.5m in venture capital to date.
Research deal with Trinity College
Collaboration with a research group within the school of biochemistry and immunology at Trinity’s Biomedical Sciences Institute.
Debt and Equity fundraising
Raised upwards of €2.5m in venture capital to date from private investors and Enterprise Ireland.
Sale to AUM Biosciences
Sold leading cancer medicine to Singapore-based biotechnology company.
Inflection Biosciences Ltd, based in Dublin and London, is a drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer. The company’s pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO).
“A successful drug for the treatment of cancer could generate several billions of dollars in revenue every year,” Darren Cunningham, CEO of Inflection Biosciences Ltd
In 2013, the company managed to secure €450,000 worth of finance from a private investor and Enterprise Ireland and we advised Inflection Biosciences on this investment. We then later acted for them in relation to a fundraising comprising of both debt and equity investments. The funding round was made up of existing shareholders and a new investor.
We have provided advice to Inflection Biosciences over the years on a variety of legal matters including intellectual property ownership, licensing, development, exploitation, and protection measures/strategies in connection with its review and development of patents and related IP in the field of oncology.
More recently, Inflection Biosciences signed a global deal for their leading cancer medicine candidate. The deal was with a Singapore-based biotechnology company, AUM Biosciences, which focuses on developing affordable cancer therapies, especially for areas with high unmet medical need in Asia. Under the deal, the company secured an upfront payment and will receive payments as it reaches certain milestones along the development path together with royalties on any future sales.